Gloom is one of the significant medical care troubles overall prompting lower usefulness and in extreme cases prompting self-destructive propensities. Stimulant and against insane medications are particularly high sought after during financial emergency and social carelessness. These medications additionally fill in as a treatment for forestalling self-destructive contemplations and endeavors.

The global anti-suicide drugs market was valued at US$ 3,818.1 million in 2018 and is expected to witness a moderate CAGR of 4.1% during the forecast period (2019 – 2027).

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/10

Market Dynamics

Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics. 

Anti-Suicide Drugs Market Overview

According to the WHO, close to 800,000 people commit suicide every year. It is considered to be the second leading cause of death among young adults in the age group of 15 years to 29 years. According to the American Foundation for Suicide Prevention, suicide is one of the leading causes of death in the U.S., with over 43,000 deaths each year. According to the American Foundation for Suicide Prevention, the suicide rate was over 12.93 per 1,000 people in 2014 in the U.S. Similarly, India, Russia, Sri Lanka, Kazakhstan, and Japan, among others have reported a high suicide rate. 

Request PDF Brochure Of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/10

Major Key Players of Anti-Suicide Drugs Market

Allergan plc, AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Johnson & Johnson, Merck & Co., Inc., NeuroRx, Inc., and Pfizer, Inc. 

Detailed Segmentation:
• Global Anti-Suicide Drugs Market, By Drug Class:
◦ Anti-Depressants and Anti-Anxiety Drugs
◦ Anti-Psychotic Drugs
◦ NMDA Antagonist
◦ Antibiotic Analog
• Global Anti-Suicide Drugs Market, By Geography:
◦ North America
▪ U.S.
• U.S. Anti-Suicide Drugs Market, By Drug Class:
◦ Anti-Depressant and Anti-Anxiety Drugs
◦ Anti-Psychotic Drugs
◦ NMDA Antagonist
◦ Antibiotic Analog
▪ Canada
• Canada Anti-Suicide Drugs Market, By Drug Class:
◦ Anti-Depressant and Anti-Anxiety Drugs
◦ Anti-Psychotic Drugs
◦ NMDA Antagonist
◦ Antibiotic Analog
Table of Contents
1. Research Objective and assumption
◦ Research Objectives
◦ Assumptions
◦ Abbreviations
2. Market Purview
◦ Report Description
▪ Market Definition and Scope
◦ Executive Summary
▪ Market Snippet By Drug Class
▪ Market Snippet By Geography
◦ Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
◦ Market Dynamics
▪ Drivers
▪ Restraints
▪ Market Opportunities

To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/10

About US

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]